A 2014 Health Wildcatters graduate, Lantern Pharma has developed a platform with diagnostics and data analytics to identify and treat cancer patients.
“Lantern will benefit immensely from the operational, strategic, and financial experience of our seasoned investors,” said Dr. Arun Asaithambi, CEO of Lantern Pharma. “The investment from GPG helps us bring the next generation of cancer therapies to patients who need them.”
Lantern Pharma uses a three-pronged approach to precision medicine, “combining a novel, clinically effective drug, diagnostic genetic tests, and data to identify and treat the right subset of cancer patients,” states the recent public release.
“Lantern Pharma is leading a wave of innovation in cancer treatment that we believe will bring the best therapies to patients who are most likely to respond,” said Clay Heighten, M.D., founding partner of GPG Ventures.
“Through molecular profiling, the cost of development is reduced and the speed to market is increased. We are thrilled that Health Wildcatters has helped bring this company to Dallas and GPG is looking forward to joining their journey as investors,” Heighten said.
To learn more about Lantern Pharma, check out their website here.